Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press31210.17650/1726-9776-2012-8-2-28-31DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиСLINICAL EXAMPLES OF THE EFFICACY OF BEVACIZUMAB + INTERFERON-ALPHA IN LOW DOSES IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMAКЛИНИЧЕСКИЕ ПРИМЕРЫ ЭФФЕКТИВНОСТИ КОМБИНАЦИИ БЕВАЦИЗУМАБ + ИНТЕРФЕРОН Α В НИЗКИХ ДОЗАХ У БОЛЬНЫХ РАСПРОСТРАНЕННЫМ ПОЧЕЧНО-КЛЕТОЧНЫМ РАКОМPopovA. M.ПоповА. М.Russian Federationapopov@mrrc.obninsk.ruKaryakinO. B.КарякинО. Б.Russian Federationapopov@mrrc.obninsk.ruMedical Radiology Research Center, Russian Academy of Medical Sciences,ObninskФГБУ МРНЦ Минздравсоцразвития России, Обнинск300620128228310508201405082014https://oncourology.abvpress.ru/oncur/article/view/312
We present clinical examples of effective use of bevacizumab with low doses of interferon alfa in the treatment of metastatic renal cell carcinoma.
Приводятся клинические примеры эффективного применения бевацизумаба с низкими дозами интерферона α в лечении метастатического почечно-клеточного рака.
metastatic renal cell carcinomatarget therapythe combination of bevacizumab with interferon-alphaметастатический почечно-клеточный рактаргетная терапиякомбинация бевацизумаба с интерфероном α.1. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2):115−24.Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2):115−24.2. Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061−8.Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061−8.3. Escudier B., Pluzanska A., Koralewski P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007 Dec 22;370(9605):2103−11.Escudier B., Pluzanska A., Koralewski P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007 Dec 22;370(9605):2103−11.4. Melichar B. et al. BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). 2011 ASCO Annual Meeting, abstr. 4546Melichar B. et al. BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). 2011 ASCO Annual Meeting, abstr. 45465. Попов А.М., Карякин О.Б., Горбань Н.А. Собственный опыт применения комбинации бевацизумаб + интерферон α-2А у больных диссеминированным почечно-клеточным раком. Онкоурология 2010;4:32−5.Попов А.М., Карякин О.Б., Горбань Н.А. Собственный опыт применения комбинации бевацизумаб + интерферон α-2А у больных диссеминированным почечно-клеточным раком. Онкоурология 2010;4:32−5.6. Albiges L., Oudard S., Negrier S. et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 2012;30(5):482−7.Albiges L., Oudard S., Negrier S. et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 2012;30(5):482−7.7. Johannsen M., Flörcken A., Bex A. et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 2009;55(6):1430−8.Johannsen M., Flörcken A., Bex A. et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 2009;55(6):1430−8.